Occurrence of ANTI-AHLG in renal transplant patients on AHLG (anti-human lymphocyte globulin).
Two patients with kidney transplants were prescribed anti-human lymphocyte gamma-globulin (AHLG) as an adjunct immunosuppressive treatment. AHLG was prepared from cultured human lymphocytes an antigen and successive anti-AHLG levels were measured using passive hemagglutination tests during and after the AHLG treatment. Anti-AHLG levels began to increase after 10-14 days of daily AHLG administration. Thereafter, the levels tends to decrease transiently by the further administration of AHLG. The titer rose again after the discontinuation of AHLG administration reaching a plateau which continued for a considerable length of time. Pretreatment levels were reverted after more than three months. The anti-sheep RBC Ab and anti-horse RBC Ab levels followed the same pattern as that seen with anti-AHLG Ab. The anti-AHLG Ab proved to be specific anti-horse gamma-globulin Ab. Alterations in the anti-AHLG levels can thus be used to monitor the optimal dosage and period of administration as well as to predict the anaphylactic reaction due to AHLG treatment. Keeping the anti-AHLG level low is mandatory to maintain good immunosuppressive conditions yet avoid anaphylactic reactions.
D000293:Adolescent; D000328:Adult; D000707:Anaphylaxis / Q000209:etiology; D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000032:analysis*; D000961:Antilymphocyte Serum / Q000009:adverse effects / Q000276:immunology*; D005260:Female; D006736:Horses / Q000276:immunology; D006801:Humans; D007165:Immunosuppression Therapy; D016030:Kidney Transplantation; D008297:Male; D012756:Sheep / Q000276:immunology; D014184:Transplantation, Homologous
D000888:Antibodies, Anti-Idiotypic; D000961:Antilymphocyte Serum